Stocks To Watch: ICICI Bank, HCLTech, Maruti, Yes Bank, Ajanta Pharma and more

ICICI Bank | Net profit at ₹10,757.5 crore compared to a CNBC-TV18 poll of ₹10,323.3 crore. Net Interest Income of ₹19,092.8 crore is also higher than the poll estimate of ₹18,982.3 crore. Gross NPA at 2.16% from 2.3% in December. Net NPA at 0.42% from 0.44% last year. Slippages at ₹5,139 crore from ₹5,714 crore sequentially. Net Interest Margin flat quarter-on-quarter but down 50 basis points year-on-year. Management said that there are ongoing discussions with the RBI with regards to IT infra and they get feedback from time-to-time. The management also expects NIMs to remain rangebound till there is a change in repo rates.

Maruti Suzuki | Net profit at ₹3,877.8 crore, lower than the poll of ₹4,104 crore. Margin misses estimates by 120 basis points to 12.2%. Year-on-year, margin improved by 170 basis points. Also declared a dividend of ₹125 per share. Profit growth of 47.8% from last year but kept in check due to higher tax expenses.

HCLTech | FY25 revenue growth guidance seen at 3-5% year-on-year, lower than CNBC-TV18’s poll of 5% – 7% growth. Constant currency revenue growth of 0.3% versus 6% in December and lower than poll of 0.4%. EBIT margin of 17.6% also lower than estimate of 18.3%. Management said that the growth guidance issued by the company is back-ended. Subdued guidance due to one large project moving offshore which will impact Q1 performance and an additional headwind of 80 basis points in Q2 due to Statestreet BPO JV exit.

IDFC First Bank Q4 Earnings, IDFC First Bank Q4 Results, IDFC First Bank quarterly earnings, IDFC First Bank quarterly results, IDFC First Bank net profit, IDFC First Bank NII, IDFC First Bank NPA, IDFC First Bank share price,

IDFC First Bank | Aiming for 1.4% to 1.5% RoA in the next 2-3 years. Q1 profit to be flat sequentially, will improve post that. Q4 should be the best profitable quarter of FY25, according to the management. FY25 loan growth seen between 22% and 23%, while deposit growth seen between 28% and 30%. Credit costs will be upfronted in H1FY25. Net profit and Net Interest Income in the fourth quarter were slightly lower than the CNBC-TV18 poll. Gross NPA at 1.88% from 2.04% last quarter, Net NPA at 0.6% from 0.68% in December.

Yes Bank | Tax write-back of ₹20.3 crore, first in three years. Lower overall provisions despite sequential rise in slippages. Write-offs at a 12-quarter high. Annualised credit cost is also at a four-quarter high. NIMs at 2.4% is a nine-quarter low. Gross NPA at 1.7% from 2% in December. Net NPA at 0.6% from 0.9% in December.

RBL Bank | Operating profit growth year-on-year is the highest in 21 quarters. Gross NPA and Net NPA is the lowest in 13 quarters. Credit-deposit ratio is the lowest in six quarters. RoA and RoE are the highest in 19 quarters. Net Interest Income met expectations, while net profit was marginally higher. Slippages at ₹680 crore from ₹666 crore. Write-offs at ₹721 crore from ₹356 crore.

L&T Finance | Net Interest Income of ₹1,909 crore below Equirus estimates of ₹1,955.2 crore. Net profit of ₹554 crore also below estimates of ₹661.6 crore. Disbursements up 24.8% year-on-year and 3.4% sequentially to ₹15,366 crore. AUM growth of 5.7% from last year to ₹85,564 crore. Gross NPA at 2.84% from 2.95%, Net NPA at 0.62% from 0.64%.

apollo hospitals share price, apollo hospitals stock, apollo hospitals shares, apollo 24/7, apollo keimed merger, keimed, apollo hospitals latest,

Apollo Hospitals | Apollo HealthCo to raise ₹2,475 crore or $300 million from Private Equity Firm Advent. To also merge Keimed, promoter-owned pharma wholesale distribution business over the next 24-30 months. The merger will be EPS accretive from year 1. Deal will involve Keimed buying out multiple JV partners. Growth capital for Apollo HealthCo worth ₹860 crore. Debt worth ₹890 crore out of ₹1,290 crore will also be retired. Aspire to have ₹25,000 crore in revenue and 7-8% margin in three years.

SBI Cards & Payment Services | Revolver rate improves for the first time in two years. Credit card business momentum has been weak with corporate spends declining 55% sequentially. Net Interest Margin at the lowest in four years. Annualised credit cost remains elevated at a nine-quarter high of 7.6%. Cards receivables at ₹50,846 crore, up 25% year-on-year. Gross NPA at 2.76% from 2.64%, while Net NPA at 0.99% from 0.96%.

Ajanta Pharma | To consider buyback of equity shares at its board meet on May 2.

IRCON | Gets order worth ₹1,198.09 crore from East Coast Railway.

IREDA | Gets “Navratna” status from the Department of Public Enterprises.